Literature DB >> 12019146

Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.

Daphne W Bell1, John Erban, Dennis C Sgroi, Daniel A Haber.   

Abstract

Carriers of one mutant allele of either BRCA1 or BRCA2 are at risk for somatic loss of the second wild-type allele, leading to the initiation of breast tumorigenesis. We identified a patient of Ashkenazi Jewish heritage with germ-line heterozygous mutations in both BRCA1 (5382insC) and BRCA2 (6174delT), who had developed three independent breast cancers by age 47. Two breast cancers demonstrated inactivation of both BRCA2 alleles but retention of the wild-type BRCA1 allele, and the third showed loss of heterozygosity for BRCA1 but not BRCA2. The observation that breast tumors arising in a double heterozygote show biallelic inactivation of either BRCA1 or BRCA2, but not both, suggests that these genetic events are functionally equivalent in initiating tumorigenesis. The distinct histopathological features of these tumors may reflect the acquisition of subsequent genetic events.

Entities:  

Mesh:

Year:  2002        PMID: 12019146

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.

Authors:  O Lavie; S Narod; F Lejbkowicz; S Dishon; Y Goldberg; O Gemer; G Rennert
Journal:  Ann Oncol       Date:  2010-10-05       Impact factor: 32.976

Review 2.  Laser capture microdissection and advanced molecular analysis of human breast cancer.

Authors:  Andrew P Fuller; Darryl Palmer-Toy; Mark G Erlander; Dennis C Sgroi
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

3.  Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.

Authors:  Ane Y Steffensen; Lars Jønson; Bent Ejlertsen; Anne-Marie Gerdes; Finn C Nielsen; Thomas V O Hansen
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

4.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Authors:  Brian J Miller; Daolong Wang; Ralf Krahe; Fred A Wright
Journal:  Am J Hum Genet       Date:  2003-09-16       Impact factor: 11.025

5.  Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer.

Authors:  Alyssa L Smith; Najmeh Alirezaie; Ashton Connor; Michelle Chan-Seng-Yue; Robert Grant; Iris Selander; Claire Bascuñana; Ayelet Borgida; Anita Hall; Thomas Whelan; Spring Holter; Treasa McPherson; Sean Cleary; Gloria M Petersen; Atilla Omeroglu; Emmanouil Saloustros; John McPherson; Lincoln D Stein; William D Foulkes; Jacek Majewski; Steven Gallinger; George Zogopoulos
Journal:  Cancer Lett       Date:  2015-11-03       Impact factor: 8.679

6.  Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.

Authors:  Natalie Tulchin; Leonard Ornstein; Steven Dikman; James Strauchen; Shabnam Jaffer; Chandandeep Nagi; Ira Bleiweiss; Ruth Kornreich; Lisa Edelmann; Karen Brown; Carol Bodian; Venugopalan D Nair; Monique Chambon; Nicholas T Woods; Alvaro Na Monteiro
Journal:  Cancer Cell Int       Date:  2013-07-15       Impact factor: 5.722

7.  Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

Authors:  Timothy R Rebbeck; Tara M Friebel; Nandita Mitra; Fei Wan; Stephanie Chen; Irene L Andrulis; Paraskevi Apostolou; Norbert Arnold; Banu K Arun; Daniel Barrowdale; Javier Benitez; Raanan Berger; Pascaline Berthet; Ake Borg; Saundra S Buys; Trinidad Caldes; Jonathan Carter; Jocelyne Chiquette; Kathleen B M Claes; Fergus J Couch; Cezary Cybulski; Mary B Daly; Miguel de la Hoya; Orland Diez; Susan M Domchek; Katherine L Nathanson; Katarzyna Durda; Steve Ellis; D Gareth Evans; Lenka Foretova; Eitan Friedman; Debra Frost; Patricia A Ganz; Judy Garber; Gord Glendon; Andrew K Godwin; Mark H Greene; Jacek Gronwald; Eric Hahnen; Emily Hallberg; Ute Hamann; Thomas V O Hansen; Evgeny N Imyanitov; Claudine Isaacs; Anna Jakubowska; Ramunas Janavicius; Katarzyna Jaworska-Bieniek; Esther M John; Beth Y Karlan; Bella Kaufman; KConFab Investigators; Ava Kwong; Yael Laitman; Christine Lasset; Conxi Lazaro; Jenny Lester; Niklas Loman; Jan Lubinski; Siranoush Manoukian; Gillian Mitchell; Marco Montagna; Susan L Neuhausen; Heli Nevanlinna; Dieter Niederacher; Robert L Nussbaum; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Sue Kyung Park; Marion Piedmonte; Paolo Radice; Christine Rappaport-Fuerhauser; Matti A Rookus; Caroline Seynaeve; Jacques Simard; Christian F Singer; Penny Soucy; Melissa Southey; Dominique Stoppa-Lyonnet; Grzegorz Sukiennicki; Csilla I Szabo; Mariella Tancredi; Manuel R Teixeira; Soo-Hwang Teo; Mary Beth Terry; Mads Thomassen; Laima Tihomirova; Marc Tischkowitz; Amanda Ewart Toland; Aleksandra Toloczko-Grabarek; Nadine Tung; Elizabeth J van Rensburg; Danylo Villano; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Jamal Zidan; Kristin K Zorn; Lesley McGuffog; Douglas Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Susan J Ramus
Journal:  Breast Cancer Res       Date:  2016-11-11       Impact factor: 6.466

8.  Five Italian Families with Two Mutations in BRCA Genes.

Authors:  Maria Teresa Vietri; Gemma Caliendo; Giovanna D'Elia; Marianna Resse; Amelia Casamassimi; Pellegrino Biagio Minucci; Concetta Dello Ioio; Michele Cioffi; Anna Maria Molinari
Journal:  Genes (Basel)       Date:  2020-12-03       Impact factor: 4.096

9.  Molecular genetics analysis of hereditary breast and ovarian cancer patients in India.

Authors:  Nagasamy Soumittra; Balaiah Meenakumari; Tithi Parija; Veluswami Sridevi; Karunakaran N Nancy; Rajaraman Swaminathan; Kamalalayam R Rajalekshmy; Urmila Majhi; Thangarajan Rajkumar
Journal:  Hered Cancer Clin Pract       Date:  2009-08-06       Impact factor: 2.857

10.  EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.

Authors:  I M Wilson; E A Vucic; K S S Enfield; K L Thu; Y A Zhang; R Chari; W W Lockwood; N Radulovich; D T Starczynowski; J P Banáth; M Zhang; A Pusic; M Fuller; K M Lonergan; D Rowbotham; J Yee; J C English; T P H Buys; S A Selamat; I A Laird-Offringa; P Liu; M Anderson; M You; M S Tsao; C J Brown; K L Bennewith; C E MacAulay; A Karsan; A F Gazdar; S Lam; W L Lam
Journal:  Oncogene       Date:  2013-10-07       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.